<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="11" family="Helvetica-Black,Bold" color="#ffffff"/>
	<fontspec id="font1" size="8" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font2" size="8" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font3" size="8" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font4" size="8" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="2" family="AkzidenzGroteskBE" color="#ffffff"/>
	<fontspec id="font6" size="15" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font7" size="16" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font8" size="16" family="AkzidenzGroteskBE,BoldItalic" color="#000000"/>
	<fontspec id="font9" size="12" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font10" size="6" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font11" size="8" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font12" size="11" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font13" size="9" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font14" size="9" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font15" size="9" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font16" size="10" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font17" size="10" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font18" size="10" family="SymbolMT" color="#000000"/>
<text top="85" left="477" width="78" height="10" font="font0" id="p1_t1" reading_order_no="1" segment_no="1" tag_type="title">Open Access<a href="http://www.biomedcentral.com/info/about/charter/"><b>Open Access</b></a></text>
<text top="42" left="311" width="245" height="7" font="font1" id="p1_t2" reading_order_no="0" segment_no="0" tag_type="text">Available online http://breast-cancer-research.com/content/6/6/R629<b>Available online</b></text>
<text top="735" left="569" width="19" height="8" font="font4" id="p1_t3" reading_order_no="74" segment_no="23" tag_type="text">R629</text>
<text top="85" left="57" width="9" height="2" font="font5" id="p1_t4" reading_order_no="2" segment_no="2" tag_type="title">Vol 6 No 6</text>
<text top="85" left="57" width="103" height="14" font="font6" id="p1_t5" reading_order_no="3" segment_no="2" tag_type="title">Research article</text>
<text top="102" left="57" width="463" height="14" font="font7" id="p1_t6" reading_order_no="4" segment_no="3" tag_type="title">Frequency of CHEK2 mutations in a population based, case–</text>
<text top="120" left="57" width="357" height="14" font="font7" id="p1_t7" reading_order_no="5" segment_no="3" tag_type="title">control study of breast cancer in young women<b>Frequency of </b></text>
<text top="137" left="57" width="443" height="12" font="font9" id="p1_t8" reading_order_no="6" segment_no="4" tag_type="text">Danielle M Friedrichsen 1 , Kathleen E Malone 2,3 , David R Doody 2 , Janet R Daling 2,3 and<i><b>CHEK2 </b></i></text>
<text top="153" left="57" width="102" height="12" font="font9" id="p1_t9" reading_order_no="7" segment_no="4" tag_type="text">Elaine A Ostrander 1<b>mutations in a population based, case–</b></text>
<text top="187" left="57" width="414" height="7" font="font3" id="p1_t10" reading_order_no="8" segment_no="5" tag_type="text">1 Divisions of Clinical Research and Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA<b>control study of breast cancer in young women</b></text>
<text top="196" left="57" width="352" height="8" font="font3" id="p1_t11" reading_order_no="9" segment_no="6" tag_type="text">2 Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA</text>
<text top="206" left="57" width="457" height="7" font="font3" id="p1_t12" reading_order_no="10" segment_no="7" tag_type="text">3 School of Public, Health and Community Medicine, Department of Epidemiology, University of Washington, Seattle, Washington, USA</text>
<text top="224" left="57" width="215" height="7" font="font3" id="p1_t13" reading_order_no="11" segment_no="8" tag_type="text">Corresponding author: Elaine A Ostrander, eostrand@fhcrc.org</text>
<text top="242" left="57" width="487" height="7" font="font3" id="p1_t14" reading_order_no="12" segment_no="9" tag_type="text">Received: 10 May 2004 Revisions requested: 6 Jul 2004 Revisions received: 5 Aug 2004 Accepted: 11 Aug 2004 Published: 22 Sep 2004</text>
<text top="261" left="57" width="264" height="7" font="font11" id="p1_t15" reading_order_no="13" segment_no="10" tag_type="text">Breast Cancer Res 2004, 6 :R629-R635 (DOI 10.1186/bcr933) http://breast-cancer-research.com/content/6/6/R629</text>
<text top="271" left="57" width="176" height="7" font="font3" id="p1_t16" reading_order_no="14" segment_no="11" tag_type="text">©  Friedrichsen et al ., licensee BioMed Central Ltd.</text>
<text top="281" left="57" width="499" height="7" font="font3" id="p1_t17" reading_order_no="15" segment_no="12" tag_type="text">This is an Open Access article distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/2.0,</text>
<text top="291" left="57" width="379" height="7" font="font3" id="p1_t18" reading_order_no="16" segment_no="12" tag_type="text">which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is cited.</text>
<text top="320" left="57" width="43" height="10" font="font12" id="p1_t19" reading_order_no="17" segment_no="13" tag_type="title">Abstract</text>
<text top="341" left="57" width="240" height="8" font="font13" id="p1_t20" reading_order_no="18" segment_no="14" tag_type="text">Introduction The cell-cycle checkpoint kinase (CHEK)2 protein</text>
<text top="351" left="57" width="240" height="8" font="font14" id="p1_t21" reading_order_no="19" segment_no="14" tag_type="text">truncating mutation 1100delC has been associated with</text>
<text top="362" left="57" width="240" height="8" font="font14" id="p1_t22" reading_order_no="20" segment_no="14" tag_type="text">increased risk for breast or prostate cancer. Multiple studies</text>
<text top="372" left="57" width="240" height="8" font="font14" id="p1_t23" reading_order_no="21" segment_no="14" tag_type="text">have found an elevated frequency of the 1100delC variant in</text>
<text top="383" left="57" width="240" height="8" font="font14" id="p1_t24" reading_order_no="22" segment_no="14" tag_type="text">specific stratifications of breast cancer patients with a family</text>
<text top="393" left="57" width="240" height="8" font="font14" id="p1_t25" reading_order_no="23" segment_no="14" tag_type="text">history of the disease, including BRCA1 / BRCA2 negative</text>
<text top="404" left="57" width="240" height="8" font="font14" id="p1_t26" reading_order_no="24" segment_no="14" tag_type="text">families and families with a history of bilateral disease or male</text>
<text top="414" left="57" width="240" height="8" font="font14" id="p1_t27" reading_order_no="25" segment_no="14" tag_type="text">breast cancer. However, the 1100delC mutation has only been</text>
<text top="425" left="57" width="240" height="8" font="font14" id="p1_t28" reading_order_no="26" segment_no="14" tag_type="text">investigated in a few population-based studies and none from</text>
<text top="435" left="57" width="57" height="8" font="font14" id="p1_t29" reading_order_no="27" segment_no="14" tag_type="text">North America.</text>
<text top="456" left="57" width="240" height="8" font="font13" id="p1_t30" reading_order_no="28" segment_no="17" tag_type="text">Methods We report here on the frequency of three CHEK2<i>Breast Cancer Res</i></text>
<text top="467" left="57" width="240" height="8" font="font14" id="p1_t31" reading_order_no="29" segment_no="17" tag_type="text">variants that alter protein function – 1100delC, R145W, and</text>
<text top="477" left="57" width="240" height="8" font="font14" id="p1_t32" reading_order_no="30" segment_no="17" tag_type="text">I175T – in 506 cases and 459 controls from a population<b>6</b></text>
<text top="488" left="57" width="240" height="8" font="font14" id="p1_t33" reading_order_no="31" segment_no="17" tag_type="text">based, case–control study of breast cancer conducted in young</text>
<text top="498" left="57" width="131" height="8" font="font14" id="p1_t34" reading_order_no="32" segment_no="17" tag_type="text">women from western Washington.</text>
<text top="341" left="315" width="241" height="8" font="font13" id="p1_t35" reading_order_no="33" segment_no="15" tag_type="text">Results There was a suggestive enrichment in the 1100delC</text>
<text top="351" left="315" width="240" height="8" font="font14" id="p1_t36" reading_order_no="34" segment_no="15" tag_type="text">variant in the cases (1.2%) as compared with the controls<i> et al</i></text>
<text top="362" left="315" width="241" height="8" font="font14" id="p1_t37" reading_order_no="35" segment_no="15" tag_type="text">(0.4%), but this was based on small numbers of carriers and the</text>
<text top="372" left="315" width="240" height="8" font="font14" id="p1_t38" reading_order_no="36" segment_no="15" tag_type="text">differences were not statistically significant. The 1100delC<a href="http://creativecommons.org/licenses/by/2.0">e http://creativecommons.org/licenses/by/2.0</a>, </text>
<text top="383" left="315" width="240" height="8" font="font14" id="p1_t39" reading_order_no="37" segment_no="15" tag_type="text">variant was more frequent in cases with a first-degree family</text>
<text top="393" left="315" width="241" height="8" font="font14" id="p1_t40" reading_order_no="38" segment_no="15" tag_type="text">history of breast cancer (4.3%; P = 0.02) and slightly enriched<b>Abstract</b></text>
<text top="404" left="315" width="241" height="8" font="font14" id="p1_t41" reading_order_no="39" segment_no="15" tag_type="text">in cases with a family history of ovarian cancer (4.4%; P = 0.09).<b>Introduction</b></text>
<text top="446" left="315" width="241" height="8" font="font13" id="p1_t42" reading_order_no="40" segment_no="16" tag_type="text">Conclusion The CHEK2 variants are rare in the western</text>
<text top="456" left="315" width="240" height="8" font="font14" id="p1_t43" reading_order_no="41" segment_no="16" tag_type="text">Washington population and, based on accumulated evidence</text>
<text top="467" left="315" width="240" height="8" font="font14" id="p1_t44" reading_order_no="42" segment_no="16" tag_type="text">across studies, are unlikely to be major breast cancer</text>
<text top="477" left="315" width="240" height="8" font="font14" id="p1_t45" reading_order_no="43" segment_no="16" tag_type="text">susceptibility genes. Thus, screening for the 1100delC variant</text>
<text top="488" left="315" width="240" height="8" font="font14" id="p1_t46" reading_order_no="44" segment_no="16" tag_type="text">may have limited usefulness in breast cancer prevention</text>
<text top="498" left="315" width="82" height="8" font="font14" id="p1_t47" reading_order_no="45" segment_no="16" tag_type="text">programs in the USA.</text>
<text top="520" left="57" width="249" height="7" font="font2" id="p1_t48" reading_order_no="46" segment_no="18" tag_type="text">Keywords: breast cancer, case–control study, CHEK2, population based<i>BRCA1</i></text>
<text top="559" left="57" width="64" height="10" font="font12" id="p1_t49" reading_order_no="47" segment_no="19" tag_type="title">Introduction</text>
<text top="570" left="57" width="240" height="9" font="font16" id="p1_t50" reading_order_no="48" segment_no="21" tag_type="text">Cell-cycle checkpoint kinase (CHEK)2 has been shown to<i>BRCA2 </i></text>
<text top="582" left="57" width="241" height="9" font="font16" id="p1_t51" reading_order_no="49" segment_no="21" tag_type="text">play a role in cell cycle regulation, apoptosis, and DNA</text>
<text top="594" left="57" width="240" height="9" font="font16" id="p1_t52" reading_order_no="50" segment_no="21" tag_type="text">repair, at least in part through phosphorylation of p53 and</text>
<text top="606" left="57" width="240" height="9" font="font16" id="p1_t53" reading_order_no="51" segment_no="21" tag_type="text">BRCA1 in response to DNA damage [1,2]. Several studies</text>
<text top="617" left="57" width="240" height="9" font="font16" id="p1_t54" reading_order_no="52" segment_no="21" tag_type="text">have reported associations of germline mutations in</text>
<text top="629" left="57" width="240" height="9" font="font17" id="p1_t55" reading_order_no="53" segment_no="21" tag_type="text">CHEK2, especially the 1100delC mutation, with increased</text>
<text top="641" left="57" width="240" height="9" font="font16" id="p1_t56" reading_order_no="54" segment_no="21" tag_type="text">susceptibility to breast and prostate cancer [3-8]. Although<b>Methods</b></text>
<text top="653" left="57" width="241" height="9" font="font17" id="p1_t57" reading_order_no="55" segment_no="21" tag_type="text">CHEK2 germline variants other than 1100delC have been</text>
<text top="664" left="57" width="240" height="9" font="font16" id="p1_t58" reading_order_no="56" segment_no="21" tag_type="text">associated with prostate cancer risk, these have not yet<i>CHEK2</i></text>
<text top="676" left="57" width="240" height="9" font="font16" id="p1_t59" reading_order_no="57" segment_no="21" tag_type="text">been shown to be enriched in breast cancer cases</text>
<text top="688" left="57" width="43" height="9" font="font16" id="p1_t60" reading_order_no="58" segment_no="21" tag_type="text">[3,4,9,10].</text>
<text top="559" left="315" width="241" height="9" font="font16" id="p1_t61" reading_order_no="59" segment_no="20" tag_type="text">The association between the CHEK2 1100delC variant</text>
<text top="570" left="315" width="241" height="9" font="font16" id="p1_t62" reading_order_no="60" segment_no="20" tag_type="text">and risk for breast cancer was initially reported by the</text>
<text top="582" left="315" width="240" height="9" font="font17" id="p1_t63" reading_order_no="61" segment_no="20" tag_type="text">CHEK2 Breast Cancer Consortium [5]. They found that the<b>Results</b></text>
<text top="594" left="315" width="240" height="9" font="font16" id="p1_t64" reading_order_no="62" segment_no="20" tag_type="text">frequency of the variant was greater among breast cancer</text>
<text top="606" left="315" width="241" height="9" font="font16" id="p1_t65" reading_order_no="63" segment_no="20" tag_type="text">patients with a positive family history of breast cancer who</text>
<text top="617" left="315" width="241" height="9" font="font16" id="p1_t66" reading_order_no="64" segment_no="20" tag_type="text">do not carry germline mutations in the BRCA1 or BRCA2</text>
<text top="629" left="315" width="240" height="9" font="font16" id="p1_t67" reading_order_no="65" segment_no="20" tag_type="text">genes, and in families with male breast cancer, as com-</text>
<text top="641" left="315" width="240" height="9" font="font16" id="p1_t68" reading_order_no="66" segment_no="20" tag_type="text">pared with healthy control individuals from the UK, The</text>
<text top="653" left="315" width="241" height="9" font="font16" id="p1_t69" reading_order_no="67" segment_no="20" tag_type="text">Netherlands, and North America [5]. Additionally, they</text>
<text top="664" left="315" width="241" height="9" font="font16" id="p1_t70" reading_order_no="68" segment_no="20" tag_type="text">noted that the frequency of the 1100delC variant did not<i>P </i></text>
<text top="676" left="315" width="240" height="9" font="font16" id="p1_t71" reading_order_no="69" segment_no="20" tag_type="text">differ significantly between breast cancer patients and</text>
<text top="688" left="315" width="240" height="9" font="font16" id="p1_t72" reading_order_no="70" segment_no="20" tag_type="text">matched control individuals from a population-based series</text>
<text top="700" left="315" width="240" height="9" font="font16" id="p1_t73" reading_order_no="71" segment_no="20" tag_type="text">of young women from the UK (age &lt; 45 years) and of older<i>P </i></text>
<text top="709" left="315" width="241" height="12" font="font16" id="p1_t74" reading_order_no="72" segment_no="20" tag_type="text">women from The Netherlands (age ≥ 55 years) [5].</text>
<text top="733" left="57" width="305" height="7" font="font3" id="p1_t75" reading_order_no="73" segment_no="22" tag_type="footnote">bp = base pairs; CHEK = cell-cycle checkpoint kinase; PCR = polymerase chain reaction.<b>Conclusion</b></text>
</page>
</pdf2xml>
